Production (Stage)
Mineralys Therapeutics, Inc.
MLYS
$16.12
$0.503.20%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.57M | 7.20M | 6.12M | 5.90M | 4.61M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.45M | 51.77M | 60.11M | 45.17M | 35.36M |
| Operating Income | -44.45M | -51.77M | -60.11M | -45.17M | -35.36M |
| Income Before Tax | -42.21M | -48.95M | -56.34M | -41.01M | -31.51M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -42.21M | -48.95M | -56.34M | -41.01M | -31.51M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.21M | -48.95M | -56.34M | -41.01M | -31.51M |
| EBIT | -44.45M | -51.77M | -60.11M | -45.17M | -35.36M |
| EBITDA | -44.43M | -51.75M | -60.10M | -45.16M | -35.35M |
| EPS Basic | -0.79 | -0.98 | -1.13 | -0.83 | -0.70 |
| Normalized Basic EPS | -0.50 | -0.61 | -0.71 | -0.52 | -0.44 |
| EPS Diluted | -0.79 | -0.98 | -1.13 | -0.83 | -0.70 |
| Normalized Diluted EPS | -0.50 | -0.61 | -0.71 | -0.52 | -0.44 |
| Average Basic Shares Outstanding | 53.16M | 49.96M | 49.82M | 49.36M | 44.90M |
| Average Diluted Shares Outstanding | 53.16M | 49.96M | 49.82M | 49.36M | 44.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |